Angiogenesis inhibitor / antiangiogenic agent
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
Investigated for treating COVID-19.
Bevacizumab-awwb (Mvasi) is biosimilar to Bevacizumab (Avastin). Approved 09/14/2017
Bevacizumab-bvzr (Zirabev) is biosimilar to Bevacizumab (Avastin). Approved 06/27/2019
Bevacizumab-maly (Alymsys) is a biosimilar to Bevacizumab (Avastin). Approved 04/13/2022
Bevacizumab-adcd (Vegzelma) is a biosimilar to Bevacizumab (Avastin). Approved 09/27/2022
Bevacizumab-tnjn (Avzivi) is a biosimilar to Bevacizumab (Avastin). Approved 12/06/2023
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see reviews of bevacizumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/13/2025
